Sana Biotechnology (SANA) said Monday that the US Food and Drug Administration has granted fast track designation to its SC291 CAR T cell therapy product candidate for the treatment of relapsed/refractory systemic lupus erythematosus.
The company said the designation is designed to facilitate the development and expedite the regulatory review process of drugs that have the potential to treat serious conditions and "fill an unmet medical need."
Sana said it is enrolling patients for SC291's GLEAM trial and it expects to release initial data from the trial in 2025.
Price: 2.97, Change: +0.19, Percent Change: +6.83
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments